Cargando…
Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older
PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762382/ https://www.ncbi.nlm.nih.gov/pubmed/29340114 http://dx.doi.org/10.18632/oncotarget.22884 |
_version_ | 1783291676960227328 |
---|---|
author | Huang, Shan Zheng, Shuyu Gong, Tuotuo Ma, Hongbing Ke, Yue Zhao, Songchuan Wang, Wenyu Jia, Lijun Zhang, Xiaozhi |
author_facet | Huang, Shan Zheng, Shuyu Gong, Tuotuo Ma, Hongbing Ke, Yue Zhao, Songchuan Wang, Wenyu Jia, Lijun Zhang, Xiaozhi |
author_sort | Huang, Shan |
collection | PubMed |
description | PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic and treatment between patients aged ≥ 80 with those aged 65–79. Focusing on patients aged ≥ 80, we employed multivariable logistic regression to identify the association between selection of RT and patients’ characteristics. Survival curve was employed to visualize the survival rate and multivariable Cox proportional hazard model was established to quantify the effect of RT on overall survival (OS) and cancer special survival (CSS). RESULTS: Patients aged ≥ 80 were more likely to be white male and have localized EC (all P < 0.001). Selection of RT in patients aged ≥ 80 were associated with cancer histology (P < 0.001), grade (P = 0.024) and stage (P < 0.001). RT significantly improved the OS (hazard ratio(HR) = 0.717) and CSS (HR = 0.722) (all P < 0.001). Further stratified analysis found the improvement were only significant in the localized (OS HR = 0.662; CSS HR=0.652) and regional stage patients (OS HR = 0.571; CSS HR = 0.581) (all P < 0.001). CONCLUSIONS: Our study suggested EC patients aged ≥ 80 benefit from RT only if the cancer is in localized/regional stage. |
format | Online Article Text |
id | pubmed-5762382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57623822018-01-16 Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older Huang, Shan Zheng, Shuyu Gong, Tuotuo Ma, Hongbing Ke, Yue Zhao, Songchuan Wang, Wenyu Jia, Lijun Zhang, Xiaozhi Oncotarget Clinical Research Paper PURPOSE: To evaluate the survival benefit of radiotherapy (RT) in esophageal cancer (EC) patients aged ≥ 80. MATERIALS AND METHODS: Records for all EC patients aged ≥ 65 years were extracted from the Surveillance, Epidemiology, and End Results database. Chi-square test compared the characteristic and treatment between patients aged ≥ 80 with those aged 65–79. Focusing on patients aged ≥ 80, we employed multivariable logistic regression to identify the association between selection of RT and patients’ characteristics. Survival curve was employed to visualize the survival rate and multivariable Cox proportional hazard model was established to quantify the effect of RT on overall survival (OS) and cancer special survival (CSS). RESULTS: Patients aged ≥ 80 were more likely to be white male and have localized EC (all P < 0.001). Selection of RT in patients aged ≥ 80 were associated with cancer histology (P < 0.001), grade (P = 0.024) and stage (P < 0.001). RT significantly improved the OS (hazard ratio(HR) = 0.717) and CSS (HR = 0.722) (all P < 0.001). Further stratified analysis found the improvement were only significant in the localized (OS HR = 0.662; CSS HR=0.652) and regional stage patients (OS HR = 0.571; CSS HR = 0.581) (all P < 0.001). CONCLUSIONS: Our study suggested EC patients aged ≥ 80 benefit from RT only if the cancer is in localized/regional stage. Impact Journals LLC 2017-12-04 /pmc/articles/PMC5762382/ /pubmed/29340114 http://dx.doi.org/10.18632/oncotarget.22884 Text en Copyright: © 2017 Huang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Huang, Shan Zheng, Shuyu Gong, Tuotuo Ma, Hongbing Ke, Yue Zhao, Songchuan Wang, Wenyu Jia, Lijun Zhang, Xiaozhi Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title | Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title_full | Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title_fullStr | Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title_full_unstemmed | Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title_short | Survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
title_sort | survival benefit evaluation of radiotherapy in esophageal cancer patients aged 80 and older |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762382/ https://www.ncbi.nlm.nih.gov/pubmed/29340114 http://dx.doi.org/10.18632/oncotarget.22884 |
work_keys_str_mv | AT huangshan survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT zhengshuyu survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT gongtuotuo survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT mahongbing survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT keyue survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT zhaosongchuan survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT wangwenyu survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT jialijun survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder AT zhangxiaozhi survivalbenefitevaluationofradiotherapyinesophagealcancerpatientsaged80andolder |